Published in Cancer Epidemiol Biomarkers Prev on February 01, 2010
Multivariate meta-analysis: potential and promise. Stat Med (2011) 5.26
HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53. Br J Cancer (2015) 0.92
Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53. Br J Cancer (2010) 0.91
Association of p53 expression with prognosis in patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol (2014) 0.89
Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. Cancer Res (2015) 0.88
In oral squamous cell carcinoma, high FAK expression is correlated with low P53 expression. Virchows Arch (2012) 0.86
Human papillomavirus and p53 expression in cancer of unknown primary in the head and neck region in relation to clinical outcome. Cancer Med (2014) 0.86
Hypoxia, blood flow and metabolism in squamous-cell carcinoma of the head and neck: correlations between multiple immunohistochemical parameters and PET. BMC Cancer (2014) 0.83
Dentin sialophosphoprotein (DSPP) gene-silencing inhibits key tumorigenic activities in human oral cancer cell line, OSC2. PLoS One (2010) 0.80
Molecular predictors of locoregional and distant metastases in oropharyngeal squamous cell carcinoma. J Otolaryngol Head Neck Surg (2013) 0.80
Unexpected predictor-outcome associations in clinical prediction research: causes and solutions. CMAJ (2013) 0.77
Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade. PLoS One (2014) 0.76
Possible implication of Mdm2 as a prognostic marker in invasive laryngeal carcinoma. Eur Arch Otorhinolaryngol (2012) 0.76
Prognostic value of some tumor markers in unresectable stage IV oropharyngeal carcinoma patients treated with concomitant radiochemotherapy. Radiol Oncol (2015) 0.75
p53 as a prognostic marker associated with the risk of mortality for oral squamous cell carcinoma. Oncol Lett (2016) 0.75
Frequent chromosomal aberrations and candidate genes in head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol (2014) 0.75
Quantifying heterogeneity in a meta-analysis. Stat Med (2002) 83.16
Practical methods for incorporating summary time-to-event data into meta-analysis. Trials (2007) 14.51
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat (2007) 12.98
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst (2008) 12.77
Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst (2005) 9.38
TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med (2007) 5.92
A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc (2009) 5.81
Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med (2006) 5.61
Papillomaviruses in the causation of human cancers - a brief historical account. Virology (2009) 5.46
EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol (2008) 5.46
Aggregate data meta-analysis with time-to-event outcomes. Stat Med (2002) 3.63
Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst (2005) 3.41
Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer (2005) 3.27
Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer (2008) 2.62
Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer (2007) 2.46
A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer (2003) 2.24
Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene (2002) 2.09
P53 overexpression in head and neck carcinoma and radiotherapy results. Int J Radiat Oncol Biol Phys (1996) 2.06
p53 alterations in human cancer: more questions than answers. Oncogene (2007) 1.94
Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer (2003) 1.92
Outcomes of p53 activation--spoilt for choice. J Cell Sci (2006) 1.88
P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol (2005) 1.79
Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes. J Virol (1992) 1.56
Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res (2002) 1.44
Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer (2009) 1.31
Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol (2005) 1.28
Identification of clinically useful cancer prognostic factors: what are we missing? J Natl Cancer Inst (2005) 1.27
Primer: an evidence-based approach to prognostic markers. Nat Clin Pract Oncol (2005) 1.04
Progression of head and neck squamous cell cancer. Cancer Metastasis Rev (2005) 1.01
p53 and cyclin D1 as prognostic factors in squamous cell carcinoma of the larynx. Laryngoscope (2003) 0.94
Clinicopathological and immunohistochemical evaluation of oral squamous cell carcinoma in patients with early local recurrence. Oral Oncol (2006) 0.93
Human papilloma virus (HPV) and p53 immunostaining in advanced tonsillar carcinoma--relation to radiotherapy response and survival. Anticancer Res (2001) 0.92
Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx. Int J Cancer (2000) 0.92
p53 mutations and human papillomavirus infection in oral squamous cell carcinomas: correlation with overall survival. J Craniomaxillofac Surg (2005) 0.90
p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx. Cancer (1994) 0.89
Prognostic significance of p53 gene mutations in laryngeal cancer. Laryngoscope (1999) 0.89
Expression of protein p27 is associated with progression and prognosis in laryngeal cancer. Laryngoscope (1999) 0.88
p53, mdm2, and p21 expression in oral squamous cell carcinomas: relationship with clinicopathologic factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2002) 0.88
The history, aetiology and epidemiology of laryngeal carcinoma. Clin Otolaryngol Allied Sci (2001) 0.87
Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify patients at high risk for local recurrence after surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys (2000) 0.87
p63 in laryngeal squamous cell carcinoma: evidence for a role of TA-p63 down-regulation in tumorigenesis and lack of prognostic implications of p63 immunoreactivity. Lab Invest (2002) 0.87
p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur Urol (2000) 0.86
The significance of PCNA and p53 protein in some oral tumors. Int J Oral Maxillofac Surg (1995) 0.84
Phenotypic alterations in Rb pathway have more prognostic influence than p53 pathway proteins in oral carcinoma. Mod Pathol (2005) 0.84
The clinicopathological significance of p53 and p21 expression in squamous cell carcinoma of hypopharyngeal cancer. Cancer Lett (2003) 0.84
Maspin expression in early oral tongue cancer and its relation to expression of mutant-type p53 and vascular endothelial growth factor (VEGF). Oral Oncol (2006) 0.84
Prognostic value of PCNA and mutant p53 expression in laryngeal squamous cell carcinoma. Cancer Invest (2004) 0.82
P53 overexpression is associated with bulky tumor and poor local control in T1 glottic cancer. Int J Radiat Oncol Biol Phys (2000) 0.82
Apoptosis in situ, p53, bcl-2 and AgNOR counts as prognostic factors in laryngeal carcinoma. Anticancer Res (1999) 0.81
Prognostic significance of Bcl-2 and p53 expression in advanced laryngeal squamous cell carcinoma. Head Neck (2001) 0.81
Overexpression of p53 protein does not predict local-regional control or survival in patients with early-stage squamous cell carcinoma of the glottic larynx treated with radiotherapy. Int J Radiat Oncol Biol Phys (1998) 0.81
p53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carcinoma. J Clin Oncol (1997) 0.81
Inducible nitric oxide synthase expression in various laryngeal lesions in relation to carcinogenesis, angiogenesis, and patients' prognosis. Acta Otolaryngol (2007) 0.80
Prognostic significance of vascular endothelial growth factor protein levels in T1-2 N0 laryngeal cancer treated with primary radiation therapy. Cancer (2007) 0.80
Expression of cyclin-dependent kinase inhibitor p21(WAF1) and p53 tumour suppressor gene in laryngeal cancer. Clin Otolaryngol Allied Sci (2000) 0.80
Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancers. Int J Cancer (1998) 0.80
TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma. J Cell Physiol (2006) 0.79
Prognostic significance of p53 and FHIT in advanced oropharyngeal carcinoma. Am J Otolaryngol (2004) 0.79
Detection of p53 protein in oropharyngeal carcinoma. Prognostic implications. Arch Otolaryngol Head Neck Surg (1996) 0.79
'Mouseyes': an aid to wound measurement using a computer. J Wound Care (1997) 0.79
Ki-67 (MIB1), p53, and Lewis-X (LeuM1) as prognostic factors of recurrence in T1 and T2 laryngeal carcinoma. Laryngoscope (2000) 0.78
P53 alteration in oral tongue cancer is not significantly associated with age at diagnosis or tobacco exposure. Tumori (2005) 0.78
Expression of p53 and p21 proteins in oral squamous cell carcinoma: correlation with lymph node metastasis and response to chemoradiotherapy. Pathol Res Pract (1998) 0.78
p53: a molecular marker for the detection of cancer. Expert Opin Med Diagn (2008) 0.78
p53 protein expression in tumours from head and neck subsites, larynx and hypopharynx, and differences in relationship to survival. Clin Otolaryngol Allied Sci (1998) 0.76
p53 tumor suppressor gene and ras oncogene mutations in hypopharyngeal squamous cell carcinomas. Int J Oncol (1997) 0.76
p53 over-expression in laryngeal carcinoma is not predictive of response to radiotherapy. Oral Oncol (1997) 0.76
p53 expression in normal, dysplastic, and neoplastic laryngeal epithelium. Absence of a correlation with prognostic factors. J Pathol (1995) 0.76
Correlation of clinicopathological parameters and biological markers related to apoptosis and proliferative activity with a clinical outcome in squamous cell carcinoma of the larynx treated with concurrent chemoradiotherapy. Auris Nasus Larynx (2001) 0.76
Overexpression of p53 nuclear protein in premalignant and malignant laryngeal lesions. Eur Arch Otorhinolaryngol (1999) 0.76
An analysis of the prognostic significance of p53 status for squamous cell carcinoma of the oral cavity treated by radiotherapy. Oral Oncol (1998) 0.76
Prognostic significance of p53/bcl-2 co-expression in patients with laryngeal squamous cell carcinoma. Laryngoscope (2000) 0.76
Clinical role of p53 and p21WAF1/CIP1 in squamous cell carcinoma of the pyriform sinus. Acta Otolaryngol (1998) 0.76
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol (2009) 5.11
Ten steps towards improving prognosis research. BMJ (2009) 3.44
Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS Med (2013) 3.13
Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med (2012) 2.52
Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. BMJ (2013) 2.31
Oropharyngeal carcinoma related to human papillomavirus. BMJ (2010) 2.09
Assessment of publication bias, selection bias, and unavailable data in meta-analyses using individual participant data: a database survey. BMJ (2012) 1.80
Meta-analysis of genetic studies using Mendelian randomization--a multivariate approach. Stat Med (2005) 1.72
Prognosis research strategy (PROGRESS) 4: stratified medicine research. BMJ (2013) 1.71
Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin Cancer Res (2011) 1.70
Indirect comparisons: a review of reporting and methodological quality. PLoS One (2010) 1.65
Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res (2004) 1.44
A multivariate meta-analysis approach for reducing the impact of outcome reporting bias in systematic reviews. Stat Med (2012) 1.34
A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance. Breast Cancer Res Treat (2011) 1.31
Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials. Clin Trials (2009) 1.28
Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. PLoS One (2011) 1.24
A matrix-based method of moments for fitting the multivariate random effects model for meta-analysis and meta-regression. Biom J (2013) 1.16
Individual participant data meta-analysis of prognostic factor studies: state of the art? BMC Med Res Methodol (2012) 1.15
Regulation of p53 and MDM2 activity by MTBP. Mol Cell Biol (2005) 1.05
Primer: an evidence-based approach to prognostic markers. Nat Clin Pract Oncol (2005) 1.04
Reporting of harms data in RCTs: a systematic review of empirical assessments against the CONSORT harms extension. BMJ Open (2013) 1.03
The science of clinical practice: disease diagnosis or patient prognosis? Evidence about "what is likely to happen" should shape clinical practice. BMC Med (2015) 1.01
p53 regulation and function in renal cell carcinoma. Cancer Res (2005) 1.01
p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets? Cancer (2010) 1.00
Expression of the chemokines MCP-1/JE and cytokine-induced neutrophil chemoattractant in early acute pancreatitis. Pancreas (2002) 0.96
MDM2 regulates dihydrofolate reductase activity through monoubiquitination. Cancer Res (2008) 0.95
Seizure recurrence after antiepileptic drug withdrawal and the implications for driving: further results from the MRC Antiepileptic Drug Withdrawal Study and a systematic review. J Neurol Neurosurg Psychiatry (2011) 0.94
Nucleolar control of p53: a cellular Achilles' heel and a target for cancer therapy. Cell Mol Life Sci (2013) 0.90
Loss of MTBP expression is associated with reduced survival in a biomarker-defined subset of patients with squamous cell carcinoma of the head and neck. Cancer (2011) 0.88
Prognosis research: toward evidence-based results and a Cochrane methods group. J Clin Epidemiol (2007) 0.87
Squamous cell carcinoma of the head and neck outside the oropharynx is rarely human papillomavirus related. Laryngoscope (2014) 0.86
MDM2 promotes cell motility and invasiveness through a RING-finger independent mechanism. FEBS Lett (2010) 0.86
Stimulation of human DNA polymerase epsilon by MDM2. Nucleic Acids Res (2003) 0.84
The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer. Int J Cancer (2013) 0.84
A refined method for multivariate meta-analysis and meta-regression. Stat Med (2013) 0.84
MDM2 interacts with NME2 (non-metastatic cells 2, protein) and suppresses the ability of NME2 to negatively regulate cell motility. Carcinogenesis (2011) 0.83
Reporting of adverse events in randomised controlled trials of antiepileptic drugs using the CONSORT criteria for reporting harms. Epilepsy Res (2011) 0.83
TargetCOPD: a pragmatic randomised controlled trial of targeted case finding for COPD versus routine practice in primary care: protocol. BMC Pulm Med (2014) 0.83
Exercise therapy for chronic low back pain: protocol for an individual participant data meta-analysis. Syst Rev (2012) 0.82
Stratified medicine in European Medicines Agency licensing: a systematic review of predictive biomarkers. BMJ Open (2014) 0.82
Multilevel mixed effects parametric survival models using adaptive Gauss-Hermite quadrature with application to recurrent events and individual participant data meta-analysis. Stat Med (2014) 0.81
Predicting infectious complications in neutropenic children and young people with cancer (IPD protocol). Syst Rev (2012) 0.80
Treatment of squamous cell carcinoma of the tongue base: irradiation, surgery, or palliation? Ann Otol Rhinol Laryngol (2007) 0.80
Individual patient data meta-analysis of survival data using Poisson regression models. BMC Med Res Methodol (2012) 0.80
Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy. BJU Int (2011) 0.79
Protocol for a systematic review of prognostic models for the recurrence of venous thromboembolism (VTE) following treatment for a first unprovoked VTE. Syst Rev (2013) 0.79
Meta-analysis of randomized phase II trials to inform subsequent phase III decisions. Trials (2014) 0.79
Methodological issues and recommendations for systematic reviews of prognostic studies: an example from cardiovascular disease. Syst Rev (2014) 0.79
Extended vertical hemilaryngectomy and reconstruction with a neovascularised tracheal autograft for advanced unilateral laryngeal tumours: a learning curve. Eur Arch Otorhinolaryngol (2013) 0.78
Survival of patients with neck recurrence following radical neck dissection: utility of a second neck dissection? Head Neck (2008) 0.78
Unexpected predictor-outcome associations in clinical prediction research: causes and solutions. CMAJ (2013) 0.77
An alternative pseudolikelihood method for multivariate random-effects meta-analysis. Stat Med (2014) 0.77
Metastatic testicular seminoma--a case report. Auris Nasus Larynx (2002) 0.77
Janus-faces of NME-oncoprotein interactions. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.75
Comment on "adjuvant therapy in pancreatic cancer: a critical appraisal". Drugs (2007) 0.75
Tissue-specific therapeutic targeting of p53 in cancer: one size does not fit all. Curr Pharm Des (2011) 0.75
Predicting microbiologically defined infection in febrile neutropenic episodes in children: global individual participant data multivariable meta-analysis. Br J Cancer (2016) 0.75